Targeting IGF-1R in the treatment of sarcomas: past, present and future
Targeting IGF-1R in the treatment of sarcomas: past, present and future
复制标题
DOI：
10.1684/bdc.2009.0915
复制
发表时间：
2009-07-01
影响因子：
1.2
通讯作者：
Helman, Lee J.
中科院分区：
文献类型：
--
作者：
Kim, Su Young;Wan, Xiaolin;Helman, Lee J.
在过去的25年里，多模式治疗的使用显著提高了肉瘤患者的治愈率。然而，对于几乎所有的转移性或复发性疾病患者，生存率仍然很低。胰岛素样生长因子（IGF）家族成员在肿瘤发生中的重要作用已被人们认识了几十年。但直到最近五年，针对胰岛素样生长因子受体1（IGF-1 R）的人源化和全人抗体才被开发出来。这些药物在临床试验中的使用已经伴随着复发性和难治性肉瘤患者的几个显着的反应。在这篇综述中，我们将重点介绍过去的临床前亮点，目前的临床试验，并讨论一些令人兴奋的研究机会，以促进未来的进展。
The use of multimodality therapy has resulted in markedly improved cure rates for patients with sarcomas in the past 25 years. However, for virtually all patients with metastatic or recurrent disease, survival remains dismal. The important role that members of the insulin-like growth factor (IGF) family play in tumorigenesis has been known for decades. But it has only been in the last five years, that humanized and fully human antibodies targeting insulin-like growth factor receptor 1 (IGF-1R) have been developed. The use of these agents in clinical trials has been accompanied by several dramatic responses in patients with recurrent and refractory sarcomas. In this review, we will focus on preclinical highlights in the past, current clinic trials and discuss some exciting research opportunities to foster advances in the future.